^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AidaBreast™

    Company:
    PreludeDx
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    1year
    PreludeDx™ announces novel test for predicting radiation therapy benefit and recurrence risk in early-stage invasive breast cancer patients (PreludeDx Press Release)
    "Prelude Corporation (PreludeDx™)...has unveiled data from an analysis of over 700 early-stage invasive breast cancer patients for AidaBreast™ - a novel biosignature that predicts 10-year recurrence rate and radiation therapy (RT) benefit - at the 41st Annual Miami Breast Cancer Conference (MBCC)."
    Clinical data
    |
    AidaBreast™